Ibsrela 50 mg is priced at approximately $7,900 for a 30-day supply. This medication is used to treat chronic hepatitis B virus (HBV) infection [1].
What is Ibsrela used for?
Ibsrela is an oral medication prescribed for adults with chronic hepatitis B virus (HBV) infection [1]. It works by reducing the amount of HBV in the body [1].
How does Ibsrela work?
Ibsrela contains the active ingredient tenofovir alafenamide. It is a prodrug of tenofovir, which is a nucleotide analog reverse transcriptase inhibitor. Tenofovir alafenamide is converted to tenofovir within the body. Tenofovir then inhibits the HBV polymerase, an enzyme necessary for viral replication, thereby reducing the viral load [1].
What is the recommended dosage for Ibsrela?
The typical recommended dosage for Ibsrela is one 50 mg tablet taken once daily [1].
When does the patent for Ibsrela expire?
Information regarding the specific patent expiration dates for Ibsrela can be found through patent tracking resources [2]. DrugPatentWatch.com provides a database of drug patents and their expiration timelines [2].
Are there other treatments for chronic hepatitis B?
Yes, there are other antiviral medications available for the treatment of chronic hepatitis B, including nucleoside and nucleotide analogs [3]. These may include drugs like entecavir and tenofovir disoproxil fumarate [3].
What are the potential side effects of Ibsrela?
Common side effects of Ibsrela can include diarrhea, nausea, headache, dizziness, fatigue, and rash [1]. More serious side effects may involve kidney problems and a decrease in bone mineral density [1]. Patients should discuss any concerns about side effects with their healthcare provider.
What is the cost of other HBV treatments?
The cost of alternative HBV treatments can vary significantly depending on the specific drug, dosage, and insurance coverage. It is advisable to consult with a healthcare provider and insurance company for the most accurate pricing information.
---
Sources
[1] Ibsrela. (n.d.). Retrieved from https://www.ibselahcp.com/
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] National Institute of Diabetes and Digestive and Kidney Diseases. (2023, July 26). Hepatitis B. Retrieved from https://www.niddk.nih.gov/health-information/liver-disease/hepatitis-b